WO2024011116A3 - Potent and selective irreversible inhibitors of irak1 - Google Patents

Potent and selective irreversible inhibitors of irak1 Download PDF

Info

Publication number
WO2024011116A3
WO2024011116A3 PCT/US2023/069627 US2023069627W WO2024011116A3 WO 2024011116 A3 WO2024011116 A3 WO 2024011116A3 US 2023069627 W US2023069627 W US 2023069627W WO 2024011116 A3 WO2024011116 A3 WO 2024011116A3
Authority
WO
WIPO (PCT)
Prior art keywords
irreversible inhibitors
irak1
potent
selective irreversible
compounds
Prior art date
Application number
PCT/US2023/069627
Other languages
French (fr)
Other versions
WO2024011116A2 (en
Inventor
John M. Hatcher
Original Assignee
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana-Farber Cancer Institute, Inc. filed Critical Dana-Farber Cancer Institute, Inc.
Publication of WO2024011116A2 publication Critical patent/WO2024011116A2/en
Publication of WO2024011116A3 publication Critical patent/WO2024011116A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The disclosure relates to compounds that act as irreversible inhibitors interleukin 1 (IL-1 ) receptor-associated kinases (IRAKs); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
PCT/US2023/069627 2022-07-07 2023-07-05 Potent and selective irreversible inhibitors of irak1 WO2024011116A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263367875P 2022-07-07 2022-07-07
US63/367,875 2022-07-07

Publications (2)

Publication Number Publication Date
WO2024011116A2 WO2024011116A2 (en) 2024-01-11
WO2024011116A3 true WO2024011116A3 (en) 2024-02-15

Family

ID=89454132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069627 WO2024011116A2 (en) 2022-07-07 2023-07-05 Potent and selective irreversible inhibitors of irak1

Country Status (1)

Country Link
WO (1) WO2024011116A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055941A2 (en) * 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9216991B2 (en) * 2012-07-10 2015-12-22 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
US9982000B2 (en) * 2015-04-22 2018-05-29 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
WO2021194982A1 (en) * 2020-03-23 2021-09-30 Dana-Farber Cancer Institute, Inc. Potent and selective irreversible inhibitors of irak1
US11542251B2 (en) * 2018-02-14 2023-01-03 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055941A2 (en) * 2005-11-03 2007-05-18 Merck & Co., Inc. Histone deacetylase inhibitors with aryl-pyrazolyl motifs
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9216991B2 (en) * 2012-07-10 2015-12-22 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
US9982000B2 (en) * 2015-04-22 2018-05-29 Rigel Pharmaceuticals, Inc. Pyrazole compounds and method for making and using the compounds
US11542251B2 (en) * 2018-02-14 2023-01-03 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof
WO2021194982A1 (en) * 2020-03-23 2021-09-30 Dana-Farber Cancer Institute, Inc. Potent and selective irreversible inhibitors of irak1

Also Published As

Publication number Publication date
WO2024011116A2 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
CR20220584A (en) Fused tricyclic kras inhibitors
MX2022006700A (en) Polyheterocyclic compounds as mettl3 inhibitors.
MX2020001218A (en) Selective inhibitors of nlrp3 inflammasome.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
WO2002096361A3 (en) 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
MY138268A (en) N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2005017190A3 (en) Mitotic kinesin inhibitors
MX2021006619A (en) Tyrosine kinase inhibitors, compositions and methods there of.
TW200510380A (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
PL1732926T3 (en) Mitotic kinesin inhibitors
MX2022005749A (en) Allosteric egfr inhibitors and methods of use thereof.
CR20240059A (en) Tricyclic compounds as inhibitors of kras
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
MX2023003677A (en) Hsd17b13 inhibitors and uses thereof.
MX2023005076A (en) Interleukin-17 inhibitors.
MX2021008667A (en) Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient.
AU2022367432A1 (en) Quinoline compounds as inhibitors of kras
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2022014925A (en) Il-17a modulators.
MX2022014924A (en) Il-17a modulators.
WO2020231739A3 (en) Compounds and methods for treating cancer
MX2023003675A (en) Hsd17b13 inhibitors and uses thereof.
WO2024011116A3 (en) Potent and selective irreversible inhibitors of irak1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23836235

Country of ref document: EP

Kind code of ref document: A2